Study to Evaluate Safety, Tolerability, and Effect of AL208 on Mild Cognitive Impairment Following Coronary Artery Bypass Graft Surgery

NCT00404014 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

234

Enrollment

INDUSTRY

Sponsor class

Conditions

Mild Cognitive Impairment

Interventions

DRUG: AL-208
DRUG: Placebo

Sponsor

Allon Therapeutics